The Healthy and At-Risk Populations program (HARP) has 34 core members representing four schools and 13 departments in total. During the current funding year, cancer-related funding for this program totaled $20.8M in total costs. Of this amount, peer-reviewed funding totaled $13.5M in total costs, including $3.4M from the National Cancer Institute. As with other programs, JCCC fosters a number of interactive activities and shared resources that support investigators in HARP. During the current grant cycle, funds from the JCCC in the form of the CCSG Developmental Funds, institutional support and philanthropic gifts to HARP total $2,043,085. These funds supported seed grants, program area leadership support, as well as the annual disparities symposium hosted by HARP in the community. The HARP program is highly interactive, with 15% of its publications reflecting intra-programmatic efforts and 11 % reporting inter-programmatic collaborations. 178 (28%) appeared in high-impact journals. Accruals to prevention trials totaled 1,186, screening 1,021, early detection/diagnostic 1,151, epidemiologic/obs/outcome 1,426, correlative 113. The goals of the HARP are to advance understanding of cancer risk and protective factors and to identify strategies to make the latest cancer prevention knowledge and technologies accessible to the population at large. HARP research spans four broad focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects supporting community engagement. Two major themes characterize the research of this program: cancer disparities and translational research (mainly T3 and T4). These themes are not mutually exclusive, and in fact most projects in the program incorporate both. Our cancer disparities research focuses on cancer prevention and control interventions to mitigate disparities in low-income, ethnic minority and other socially and medically underserved populations in Los Angeles and beyond and has brought recognition to UCLA as one of the premier cancer disparities research programs in the nation.

Public Health Relevance

The Healthy and At-Risk Populations Program (HARP) has 34 core members conducting work within four focus areas: 1. cancer risk and protective factors/etiology, 2. primary prevention, 3. screening/early detection, 4. infrastructure projects to support community engagement. Two major themes, which cut across the four focus areas, characterize the research in HARP: cancer disparities and translational research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Wu, Sheng; Wong, Weng Kee; Crespi, Catherine M (2017) Maximin optimal designs for cluster randomized trials. Biometrics 73:916-926
Douaisi, Marc; Resop, Rachel S; Nagasawa, Maho et al. (2017) CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol 198:2310-2319
Qi, Hangfei; Chu, Virginia; Wu, Nicholas C et al. (2017) Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc Natl Acad Sci U S A 114:2018-2023
Lu, Jianqin; Liu, Xiangsheng; Liao, Yu-Pei et al. (2017) Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun 8:1811
Castaneda, Julie T; Harui, Airi; Roth, Michael D (2017) Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation. J Neuroimmune Pharmacol 12:544-554
Casillas, Jacqueline; Goyal, Anju; Bryman, Jason et al. (2017) Development of a text messaging system to improve receipt of survivorship care in adolescent and young adult survivors of childhood cancer. J Cancer Surviv 11:505-516
Su, Yapeng; Wei, Wei; Robert, Lidia et al. (2017) Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc Natl Acad Sci U S A 114:13679-13684
Demer, Linda L; Tintut, Yin; Nguyen, Kim-Lien et al. (2017) Rigor and Reproducibility in Analysis of Vascular Calcification. Circ Res 120:1240-1242
Kiyohara, M H; Dillard, C; Tsui, J et al. (2017) EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene 36:5793-5807
Dock, Jeffrey; Ramirez, Christina M; Hultin, Lance et al. (2017) Distinct aging profiles of CD8+ T cells in blood versus gastrointestinal mucosal compartments. PLoS One 12:e0182498

Showing the most recent 10 out of 721 publications